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Introduction
Uterine cancers can be divided in uterine carcinoma and the 
rare group of uterine sarcoma. Uterine high grade sarcomas 
in general and recurrent endometrial carcinomas are highly 
aggressive. Standard treatment modalities are poor in number 
and have limited success. There is a clear need for better and 
less toxic treatment modalities for uterine tumors (1, 2).
During tumor growth, the immune system interacts with 
and attempts to destroy the tumor. The immune system 
discriminates malignant cells from their benign counterparts 
because tumor cells aberrantly express tumor-associated 
antigens (TAA). The observation that tumors are frequently 
infiltrated by tumor infiltrating lymphocytes (TIL) led to the 
development of the cancer immunosurveillance theory by 
Burnet and Thomas in 1957. In this view, tumor growth can 
be regarded as a multistep process termed “immunoediting” 
during which the immune system continuously interacts 
with and attempts to destroy the tumor. The appearance 
of clinically detectable tumors can thus be explained as a 
failure of the immune system to control the tumor (3). This is 
probably related to the link between inflammation and cancer, 
implicating that the chronic activation of the immune system 
ultimately leads to immune dysfunction. Supporting this is the 
fact that several chronic inflammatory diseases are associated 
with an increased risk of cancer (e.g. inflammatory bowel 
disease and colon cancer, prostatitis and prostate cancer, 
hepatitis and liver cancer) (4). Although several immune 
cells can have an anti-tumor role (e.g. mature DC, cytotoxic 
T lymphocytes, NK cells), the chronic inflammatory tumor 
microenvironment inhibits their function, thus contributing to 
immune escape. 
Immunotherapy can be defined as the treatment of 
cancer by inducing, enhancing or suppressing an immune 
response. Immunotherapy is based on the recognition of TAA, 
leading to the induction of a specific anti-tumor response 
without harming healthy surrounding tissue. There are two 
distinct types of immunotherapy, namely active and passive 
immunotherapy. Active immunotherapy implies cancer 
vaccines, where the immune response has to be elicited 
by the human body. This can be achieved in several ways: 
injection of a (modified) peptide/protein, vaccination with 
recombinant DNA or viral vectors, cellular therapy using gene-
modified tumor cells or tumor antigen loaded dendritic cells 
(DC). The differences and advantage of DC immunotherapy 
over the other techniques is that DC are  professional antigen 
presenting cells (APC) capable of inducing naïve anti-tumor 
T cells, whereas the other modalities require uptake by 
host cells, which include DC but also non-professional APC 
(5). Passive immunotherapy implies the administration of 
preformed specific immunotherapeutic agents, tumor-specific 
antibodies or T cells. The administration of monoclonal 
antibodies against tumor antigens in HER2-positive breast 
cancer (Trastuzumab), CD20-expressing B-cell lymphomas 
(Rituximab), and head and neck, lung, and colorectal cancers 
that express the epidermal growth factor receptor (Cetuximab) 
are the most known and clinically effective representatives 
of this group (6). However, it is also possible to administer 
tumor-specific T cells, which are either expanded from TIL or 
genetically modified to express a known antigen-specific T 
cell receptor (TCR) (7). Experiences in this field are limited 
and mainly focused in melanoma. Passive immunotherapy 
can also focus on the modulation of immunosuppressive 
effects (CTLA-4, PD-1, IDO,…), though clinical trials are still 
limited with remarkable side-effects for some agents (8, 9).  
However, tumor cells change rapidly and are thereby able 
to escape immune surveillance, resulting in immunological 
tolerance of the body to cancer. The challenge of 
immunotherapy is to break this tolerance and to tilt the effect 
towards immune surveillance. 
The Immune System in Uterine Tumors
Endometrial carcinoma displays several features of 
inflammation, including cytokine secretion and leukocyte 
infiltration in tumors. It is hypothesized that hormonal 
alterations and genetic changes (e.g. NF-κB activation, COX-
2 upregulation,…) in tumor cells create a pro-inflammatory 
milieu that facilitates cancer progression (4). Several cytokines 
and chemokines have been associated with endometrial 
carcinoma, among which TNFα, IL-6, IL-8, TGF-β. Another 
soluble mediator indicating chronic immune activation is 
neopterin, which is increased in endometrial carcinoma 
(10). Moreover, neopterin production is associated with 
indoleamine 2,3-dioxygenase (IDO) activity, a mechanism 
implicated in the suppression of T cell responses which is 
involved in endometrial cancer (11). Endometrial cancer cells 
also have been shown to express molecules to escape anti-
tumor immunity, e.g. B7-H4, COX-2, CXCR4, STAT3.
In addition to mediators expressed by tumor cells 
themselves, both innate and adaptive immune cells are recruited 
into endometrial tumors. Tumor-associated macrophages 
(TAMs) have pleiotropic functions, which can influence 
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tumor growth. The role of TAMs in endometrial carcinoma is 
complex. Located in close contact with cancer cells, they have 
a beneficial effect on relapse-free survival, but TAMs located 
in necrotic tumor tissue are linked with tumor recurrence 
(12). Moreover, TAMs secrete matrix metalloproteinases 
and induce angiogenesis which promote tumor progression 
(13). Neutrophils are also increased in endometrial cancer, 
but their exact role is still enigmatic. Endometrial tumors are 
frequently infiltrated by T lymphocytes as well. Tumor-specific 
CD4+ and CD8+ T cells are implicated in tumor eradication. 
Hence, the presence of CD8+ cytotoxic T lymphocytes at the 
invasive border of endometrioid endometrial carcinoma leads 
to a more favorable outcome for the patient (14), suggesting 
an effective cytotoxic effect of these cells. On the other hand, 
CD8+ lymphocytes present in primary untreated stage IA-IIIA 
endometrial cancer, show upregulation of inhibitory natural 
killer receptors, an effect that possibly is mediated through 
TGF-β. However, this upregulation prevents the cytotoxic 
function of these lymphocytes at the HLA recognition level, 
thus causing an important tumor evasion strategy, since 
non-classical HLA molecules are upregulated in cancer (15). 
CD4+ FoxP3-expressing regulatory T cells (Treg) play an 
important role in the prevention of auto-immunity and in the 
controlled downregulation of undesired immune responses. 
Unfortunately, in many tumors, they will also suppress 
endogenous and induced antitumor immune responses. 
However, in endometrial carcinoma, the presence of Treg 
is debatable. Fattorossi et al. showed their presence in the 
tumor-draining lymph nodes of 26 patients (16), whereas 
Giatromanolaki et al. demonstrated less Treg in 79 stage 
I endometrial carcinoma patients compared to normal 
endometrium (17). More recently, the field of myeloid-derived 
suppressor (MDSC) cells has gained more attention. They 
have multiple action pathways, including inhibition of the innate 
and the adaptive immunity, supporting tumor angiogenesis, 
facilitation of Treg development and limiting the availability of 
mature and functional DCs (18). To our knowledge, the role of 
these cells has not been explored in endometrial carcinoma.
The role of the immune system in uterine sarcoma is much 
less evident and poorly studied. However, a recent publication 
showed the association of uterine sarcoma with systemic 
inflammation, as measured by an enhanced neutrophil to 
lymphocyte ratio in these patients (19). TIL can be detected 
in uterine sarcoma, but these cells can sometimes harbor 
chromosomal aberrations which might negatively impact their 
functionality (20). Like in endometrial carcinomas, neopterin 
levels have been shown to be increased in patients with 
uterine sarcoma, indicating the activation of cell-mediated 
immunity (21).
Immunotherapy in Uterine Tumors
Although ample research has been done in several malignant 
disorders, such as prostate cancer, malignant glioma and 
melanoma, little has been done to date in uterine tumors, 
in spite of, albeit quite limited, evidence supporting uterine 
tumors as a valid target for immunotherapy. Several tumor 
antigens have for example been described for these tumors 
yet remained largely unexplored in an immunotherapeutic 
setting. In addition, several groups have reported immune 
system involvement in uterine tumors, described in the 
previous section. The immunotherapeutic strategies that 
have been explored so far in uterine cancer are further 
elaborated on in the following sections, after which possible 
new strategies arising from other cancer types or in vitro 
observations will be discussed.
Immunotherapy For Endometrial Carcinomas
Table 1 gives an overview of immunotherapeutic strategies 
that have been tested in vitro, in animals or in humans. Three 
major conclusions can be drawn. 
First, there are only a few reports in the in vitro or animal 
setting, and of those strategies that have been explored first 
at experimental level, only one was brought to clinic. The 
opposite is true as well: most clinical attempts in endometrial 
carcinoma have no fundamental basis. It is true that the 
majority of the techniques has been explored in other tumors, 
both fundamentally and clinically, but in vitro or animal work 
with endometrial carcinoma cells preceding most clinical 
attempts in Table 1 are non existing. At first, this seems 
surprising. At second, it seems more or less acceptable. 
Immunotherapy cannot be seen separately from the existing 
immune mechanisms in the tumor and the human body, which 
are undoubtedly influencing the clinical result of the therapy. 
This effect can be partially mimicked in mice but is not fully 
representative for the in vivo situation in humans.
Secondly, immunotherapy in endometrial carcinoma 
is in its infancy. The studies are very limited in number and 
grouped in time. The oldest immunotherapeutic attempt 
dates already from 1987 (22) but between 1991 and 1999, 
the interest for immunotherapy in endometrial carcinoma was 
lost. Eventually, only 13 studies have been published, using 
very diverse techniques. Four of them use adoptive T cell 
transfer (22-25), four studies – the most recent ones - focus 
on a tumor-associated antigen (WT1, EpCAM, TF) (26-29), 
two studies use a general anti-tumor agent (tumor necrosis 
factor alpha and gonadotropin-releasing hormone analogue 
conjugates (30, 31)), two studies use DC immunotherapy 
(27, 32) and three studies are published using the injection 
of a peptide, of which there was direct (26, 33) or indirect 
(34) evidence that the peptide/protein was also present in the 
tumor. This diversity makes it difficult to draw firm conclusions 
about the effectiveness of a specific therapy or to select one 
to explore further. 
Immunotherapy For Uterine Sarcomas
Table 2 gives an overview of the immunotherapy trials in 
uterine sarcoma. The situation is even worse compared to 
the endometrial carcinoma group. Only 3 clinical studies, 
less than a decade old, with a total of 4 patients have been 
published (26,33,35). There are no in vitro or animal data 
available. Although this is disappointing for an aggressive 
disease, it is not surprising. Uterine sarcomas are rare and 
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therefore studies are hard to set up. In vitro or animal work 
could be set up with commercial cell lines, though the most 
used commercial cell lines SK-UT-1 and MES-SA are old 
lines. Since the knowledge about the histology of uterine 
sarcomas has changed tremendously over time, the exact 
diagnosis of SK-UT-1 and MES-SA then is questionable 
now and thus not completely reliable for further experiments. 
The culture of new primary tumors would be ideal for further 
experiments, though this technique is hampered by its risk of 
overgrowth by fibroblasts. 
Search For New Strategies
New Targets: Tumor Associated Antigens 
Immunotherapeutic targets can consist of one or more defined 
TAA or a tumor-derived mixture of unknown TAA. Several TAA 
are validated for immunotherapy of uterine tumors such as 
for example several cancer testis antigens (36), MUC1 (37), 
universal TAA such as hTERT or antigens targeting tumor cell 
survival such as survivin. Despite their description in uterine 
tumors, as well as encouraging animal studies using the 
same antigens in different pathological conditions or in vivo 
Table 1. Immunotherapeutic strategies tested in vitro.
Inoue M et al, 
1987 (22)
Shimizu H 
et al, 1989 (23)
Steis RG 
et al, 1990 (24)
Hersh EM 
et al, 1991 (30)
Palyi I et al,
1999 (31)
Santin A et al, 
2000 (25)
Santin A et al,
 2002 (32)
Tsuda N et al, 
2004 (33)
Kaumaya PT 
et al, 2009 (34)
Ohno S et al, 
2009 (26)
Coosemans A 
et al, 2010 (27)
Cocco E et al, 
2010 (group 
Santin) (28)
El-Sahwi et al, 
2010 (group 
Santin) (29)
Endometrial
carcinoma 
Endometrial 
carcinoma
Endometrial 
carcinoma
Endometrial 
carcinoma
Endometrial 
adenocarcinoma
Endometrioid 
endometrial
carcinoma
Serous 
endometrial 
carcinoma
Endometrial 
carcinoma
Endometrial 
carcinoma
Endometrioid 
endometrial 
carcinoma
Serous 
endometrial 
carcinoma
Serous 
endometrial 
carcinoma
Serous 
endometrial 
carcinoma
Animal 
study
Animal 
study
Clinical 
phase I
Clinical 
phase II
In vitro
Case 
report 
Clinical 
phase I
Clinical 
phase I
Clinical 
phase I
Clinical 
phase I
Case 
report
In vitro
In vitro
Adoptive transfer of lymphokine-activated 
killer (LAK) cells
Adoptive transfer of lymphokine-activated 
killer (LAK) cells +/- rIL-2 +/- lentinan in 
nude mice inoculated with endometrial 
carcinoma cell lines
Adoptive transfer of lymphokine-activated 
killer (LAK) cells + rIL-2 intraperitoneally
Injection of recombinant tumor necrosis 
factor alpha
Application of gonadotropin-releasing hor-
mone analogue conjugates on cell lines
Injection of specific T cells, created by the 
in vitro challenging of T cells with DCs 
loaded with whole tumor lysate
Injection of DCs loaded with whole tumor 
lysate
Injection of maximal 4 peptides to which 
specific T cells were detectable in blood + 
Montanide ISA51
Injection of two chimeric, B-cell epitopes 
derived from HER2 extracellular domain 
in a combination vaccine with a promis-
cuous T-cell epitope (ie, MVF) and nor-
muramyl-dipeptide as adjuvant emulsified 
in SEPPIC ISA 720
Injection of a modified 9-mer WT1 peptide
Injection of WT1-RNA loaded DC
Chromium release assay after application 
of human immuno-conjugate molecule 
(hI-con1) (= antibody-like molecule 
targeted against tissue factor (TF)) on 
cell lines
Chromium release assay after application 
of MT201 (adecatumumab), a human 
monoclonal antibody against EpCAM, on 
cell lines
Severe growth retardation of the tumor 
in nude mice
Tumor growth is inhibited
PD
Not specified
Strong decrease of colony formation 
and proliferation of tumor cells
Transient decrease of tumor marker, 
stabilization of tumor marker during 
therapy, infiltration of these specific T 
cells into small tumoral lesions
All patients induced CD8+ CTL, able to 
kill autologous tumor cells in vitro
PD after 2m*
1 PR for 4 years and 1 no clinical 
response
PD after 3m*
Transient decrease of tumor marker 
and immunological response
65.6% of tumor cells was killed
33% of tumor cells was killed
*counted from the start of immunotherapy
1
3
1
2
1
1
3
1
2
1
1
3
5
Author N
Type of 
carcinoma Phase Procedure Results
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human studies in other gynecological tumors (38) or non-
gynecological tumors, many of these antigens have remained 
largely unexplored in an immunotherapeutic setting. 
Until now the majority of antigen-focused 
immunotherapeutic studies in general have used a single 
antigen as a target. However, more and more arguments are 
arising for settings using a combination of multiple antigens. 
There are three major advantages to this type of approach. 
First of all, by using a combination of several antigens, the 
risk of immune escape is reduced. Secondly, by using multiple 
antigens, the group of tumors and hence the patient group 
that can be targeted with one treatment approach is much 
larger. For example, patients suffering from tumors that are 
negative for one particular antigen, but positive for another 
may benefit from the same therapy if both those antigens 
are present as a target in the treatment cocktail. Lastly, by 
including anti-apoptosis factors as a target, the survival of the 
tumor itself can be attacked as well.
Finally, as an alternative to selected antigens, an 
immunotherapeutic strategy using all of the antigens present 
in the tumor (e.g. using total tumor RNA) can be used. This 
treatment, however, calls for a certain amount of caution, due 
to the possible occurrence of autoimmune responses, even 
though a certain amount of autoimmunity is necessary for 
efficient tumor eradication. Nevertheless, it should be closely 
monitored.
Immunomodulators
As described above, antibodies targeting inhibitory immune 
checkpoints have recently emerged as potent anti-cancer 
drugs that release the brakes of the immune system. 
The most prominent example is anti-CTLA-4 (Ipilimumab 
or Tremelimumab) that acts by countering the negative 
feedback that is induced upon T cell activation in order to 
limit the immune response. Ipilimumab has been shown to 
have a beneficial effect on overall survival in phase III trials 
in melanoma and has also been explored in prostate cancer, 
pancreatic cancer, non-Hodgkin lymphoma, renal cell cancer, 
albeit to lesser extent. However, the use of Ipilimumab is 
associated with severe immune-related adverse events that 
often correlate with clinical efficacy; these side effects can 
usually be easily managed by steroid treatment, without 
affecting the anti-tumor immune response (8,39). Another 
immune checkpoint that has been explored as a target 
in cancer therapy is PD-1. PD-1 is an inhibitory receptor 
expressed on activated T cells and its ligands, PD-L1/B7-H1 
and PD-L2/B7-DC, are frequently expressed by tumor cells. 
Recently, the anti-PD-1 antibody MDX-1106 was tested in 
phase I clinical trial and reported to be safe and well tolerated, 
with some anti-tumor activity. More importantly, anti-PD-1 
antibody treatment seems to be associated with less immune-
related adverse events compared to Ipilimumab (9). 
Other tumor-induced immunosuppressive mechanisms 
activated in uterine tumors (IDO, COX-2, STAT3, Treg) 
can also be targeted by specific agents. In vitro treatment 
of endometrial cancer cells with curcumin has been shown 
to result in decreased IL-6 production and decreased IL-6 
induced STAT3 phosphorylation and thus constitutes a 
promising new anti-cancer drug (40). In another in vitro study, 
the COX-2 inhibitor NS-398 was able to inhibit endometrial 
cancer cell proliferation, viability and invasion (41). 
Immunomodulatory drugs (IMiDs) are thalidomide 
analogues which possess immunomodulatory, anti-
angiogenic, anti-inflammatory and anti-proliferative effects. 
Till now, IMiDs have been mostly tested in hematological 
malignancies, but they could possibly also be beneficial in 
solid tumors (42). It remains to be elucidated which of the in 
vitro properties of IMiDs will mediate their prominent mode of 
action in vivo. The parent drug thalidomide has been tested in 
uterine cancer, but showed limited or no efficacy, so it remains 
to be elucidated whether the optimized analogues will show 
enhanced effectiveness (43, 44).
Adoptive T Cell Ttherapy
Adoptive T cell therapy is based on using cancer patient 
immune cells that are grown outside of the patients body and 
re-infused in much larger numbers (7). This kind of therapy can 
be combined with other treatments such as chemotherapy or 
the addition of IL-2 in order to increase its efficacy. Most data 
so far concerning adoptive T cell transfer have been obtained 
in melanoma, by the group of Rosenberg, the first reports 
dating back to 1988 (Rosenberg et al in (7)). Melanoma 
was chosen as a target because of frequent observations of 
TIL and the presence of many described TAA. This type of 
approach has also already been tested in uterine tumors, as 
discussed above (22-25), with mostly encouraging outcome.
Using adoptive T cell transfer, several important factors 
hampering the antitumor T cell response can be circumvented 
by in vitro manipulation, reviewed by Hawkins et al. (7). Due 
to the in vitro culturing of T cells, immune regulation causing 
reduced in vivo expansion of antitumor T cells can be 
Table 2. Immunotherapy trials in uterine sarcoma.
2
1 
1
Hernando JJ et al, 2002 (35)
Tsuda N et al, 2004 (33)
Ohno S et al, 2009 (26)
Uterine sarcoma
Carcinosarcoma 
Carcinosarcoma
Clinical 
phase I
Clinical 
phase I
Clinical 
phase I
One patient had PD after 3 m, 
the other patient after 6m* 
PD after 5m*
PD after 3m*
Injection of DCs loaded with whole 
tumor lysate and KLH (Keyhole 
Limpet Hemocyanin)
Injection of maximal 4 peptides to 
which specific T cells were detect-
able in blood + Montanide ISA51
WT1 peptide immunotherapy
*counted from the start of immunotherapy
Author Number Type of sarcoma Phase Procedure Results
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circumvented. In addition, T cell properties can be genetically 
modified in vitro. This technique is often used to generate 
so-called chimeric antigen receptors (CAR), combining the 
antigen specificity of an antibody and the killing capacity of a T 
cell and thereby improving the antitumor capacity of adoptively 
transferred T cells (45). However, several concerns have 
arisen in studies using this type of immunotherapy, such as 
significant “on-target toxicity” (Morgan et al in (7)), and toxicity 
due to mispairing of endogenously present and genetically 
introduced TCR (Schumacher et al. in (7)). The occurrence 
of these side effects added to the fact that transduced T cells 
have the capacity to sustain themselves for a very long period 
of time, which may cause an accumulation of adverse events 
(45), warrants for careful design of clinical trial using adoptive 
T cell transfer as an immunotherapeutic strategy.
Cancer Vaccines
Cancer vaccines seek to induce a tumor specific immune 
response, distinct from self antigens and to provide long term 
memory to prevent tumor recurrence. Cancer vaccines can 
be designed in several ways. 
First, antigens can be loaded onto APC, most often 
DC, leading to a T cell response. Moreover, DCs have also 
been shown to be strong activators of natural killer cells 
and natural killer T cells, thus linking innate and adaptive 
immune responses. DC can be cultured in vitro starting from 
monocytes (46) and they can be loaded with one or more 
TAA or with whole tumor cell products (obtained by tumor 
lysates, total tumor RNA,…) or with a combination of defined 
TAA and whole tumor products, which is a prerequisite for 
tumors without well defined TAA, such as glioblastoma (47). 
DC immunotherapy has been applied in several tumors with 
varying success, of which melanoma and glioblastoma are 
the biggest representatives (48, 49). 
Secondly, TAA can be incorporated into a viral vaccine 
vector (amongst them poxvirus-based and adenovirus-based 
vectors) which is injected in APC or taken up by APC after 
cell death of the initially vector-infected cell, mostly epithelial 
cells. This is a less explored strategy, though it has been used 
in ovarian cancer and prostate cancer (50). The advantages 
are their ease to be engineered and their capacity to carry 
large amounts of genetic material. The disadvantage is that 
the antibody response to the viral proteins dominates over the 
desired response of the encoded TAA.  
Thirdly, a cancer vaccine can consist solely of antigen-
derived peptide(s) that elicit an immune response. Although 
promising and largely explored, its dependence of the MHC 
antigen status of the patient and the fact that not all MHC-
restricted peptides of a tumor specific protein are yet known, 
are two serious limitations. 
Fourthly, TAA can be delivered through DNA vaccines. 
DNA vaccines are safe and can easily be manufactured. 
Because of their low immunogenicity level, DNA fusion 
vaccines have been developed. TAA can be associated with 
pro-inflammatory molecules like toll-like receptor agonists 
to activate APC or they can be fused CD4 epitopes like the 
fragment C of tetanus toxin, critical for the induction of long-
term antitumor immunity (51).
Combination of Immunotherapy With Existing 
Treatments
It has become clear that the success of immunotherapy is not 
only the merit of the injected product, but the whole of existing 
immunotolerance and immunosurveillance in the human 
body. Moreover, immunotherapy by itself might result in the 
rise of inhibitory cells (52). Therefore, it is broadly accepted 
that, in order to be effective, immunotherapeutic agents 
should be combined with other modalities. In this section, 
promising combinations of immunotherapeutic agents with 
other treatment modalities will be highlighted; however, since 
few studies are performed in uterine cancer, concepts from 
other tumors will be discussed.
Combination With Chemotherapy
The combination of chemotherapy and immunotherapy may 
have beneficial results in this respect. Some examples of 
chemotherapy suppressing inhibitory cells have already 
been explored in literature. Doxorubicin and paclitaxel at 
maximally tolerated dose were shown to help break tolerance 
to “self” cancer antigens and enhanced cancer vaccine 
efficacy. The exact molecular function of these drugs on 
particular immune cells subsets has recently started to be 
clarified. Also, gemcitabine used at conventional doses was 
found to significantly reduce the number of MDSCs in the 
spleen of treated mice, whereas other leukocytes were not 
affected. Finally, lower doses of chemotherapy have been 
proven synergistic with immunotherapy by depleting Treg 
and retaining memory T cells in mice, as exemplified for 
cyclophosphamide (53). 
Besides inhibiting immunosuppressive cells, the 
beneficial effects of chemotherapy could be attributed to the 
induction of immunogenic tumor cell death, which increases 
the antigen uptake by antigen presenting cells, leading to in 
situ immunization against tumor antigens. This is the case 
for doxorubicin. Chemotherapy might also lead to direct 
activation of mature DC (this was proven for doxorubicin and 
paclitaxel) or their effector mechanisms. In this respect, the 
chemotherapeutic dose is critical, since too high doses can 
negatively impact immune cell function. 
The combination with chemotherapy can result in striking 
effects. As an example, we highlight the study of Antonia et al 
(54). Twenty-nine patients with extensive stage small cell lung 
cancer were treated with p53-DC immunotherapy. Although 
half of the population had an immunological response, clinical 
response was absent in 96.5%. However, if patients received 
chemotherapy after DC treatment, 62% showed a clinical 
response, thus improving overall survival, compared to the 
historic response rate in this group. The clinical response was 
closely associated with the presence of an immunological 
response. 
Another mechanism that could attribute to the synergy 
between chemotherapy and immunotherapy is the fact that 
some mechanisms of chemotherapeutic drug resistance 
are associated with expression of proteins that are targets 
of T cell responses. This is exemplified by the induction of 
survivin upon cisplatin resistance in ovarian cancer (55). 
Thus, immunotherapy targeting these antigens is appealing 
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to combine with chemotherapy (56). In addition, explaining 
the success of the combination of chemotherapy with 
immunotherapy may be due to the fact that a chemotherapy 
response exposes new/other antigenic epitopes, to which an 
efficient immune response can subsequently be arisen.
Combination With Targeted Therapies
The combination of immunotherapy with standard therapy 
might even result in a synergistic effect. To this respect, 
especially tyrosine kinase inhibitors which were originally 
developed as anti-angiogenic drugs show great potential 
because of their immunomodulatory effects on different 
immune cell types. Specifically for WT1, a case study 
combining Imatinib and WT1 peptide immunotherapy in a 
chronic myeloid leukemia patient has been described. The 
residual disease that was left from the treatment with Imatinib 
alone was reduced if both treatments were combined (57). 
Another tyrosine kinase inhibitor, Sunitinib, also shows great 
potential for combination with immunotherapeutic agents, 
because of its beneficial effects on type 1 immune responses 
and inhibitory effects on both Treg and MDSC (58, 59). 
The combination of Sipuleucel-T (APC vaccine loaded with 
prostatic acid phosphatase) with Bevacizumab (anti-VEGF) 
has been explored in prostate cancer patients resulting in 
PSA declines and alterations in PSA doubling time (60). 
Combination of Different Immunotherapeutic Regimens
Several cytokines have been described to increase the 
potential of immunotherapeutic regimens. Some are predicted 
to function through APC (e.g. IFNα, IL-12 and GM-CSF), while 
other cytokines selectively support activation or maintenance 
of the effector T cell repertoire (e.g. IL-2, IL-7, IL-15, IL-18, 
IL-21). However, dosing needs to be performed cautiously, 
since some cytokines can have considerable side effects 
(e.g. IFNα, IL-2) or could induce inhibitory immune cells (e.g. 
IL-2, GM-CSF) (61). Immune activators like Toll-like receptor 
agonists that induce in vivo cytokine secretion could mediate 
the same effects. However, their use is confounded by their 
limited availability in GMP quality and their toxicity profile 
upon systemic administration. Nonetheless, encouraging 
data have been reported with regard to the combination of 
different vaccine modalities with TLR agonists like imiquimod, 
CpG oligonucleotides and monophosphoryl lipid A (MPL) (62). 
The combination of an anti-tumor vaccine with blockade 
of immune inhibitory mechanisms like CTLA-4 or PD-1 is 
an attractive combination. However, studies combining anti-
CTLA4 antibodies Ipilimumab or Tremelimumab with a gp100 
or MART1 vaccine in melanoma patients emphasizes that 
careful timing of both treatments is probably critical (8, 63). 
PD-1 blockade combined with a GM-CSF secreting tumor 
vaccine has been shown to induce improved anti-tumor 
responses in a mouse model (64). 
Removal of inhibitory cell populations such as Treg 
and MDSC is also a promising option for combination with 
a vaccine regimen. However, effective drugs to deplete 
these cell types are still under investigation and conflicting 
observations have been made in cancer patients. For example, 
low-dose cyclophosphamide, anti-CD25 (Daclizumab), IL-2 
immunotoxin (denileukin diftitox, ONTAK) all have been 
described to significantly deplete Treg which could not 
always be reproduced by others. This is probably due to 
the lack of a good Treg marker in humans, which makes it 
difficult to compare studies where different markers were 
used. Nevertheless, promising results have been reported 
using Treg depleting regimens and tumor vaccines (65, 
66). Selective depletion of MDSC has not been reported to 
date. However, several drugs have been reported to mediate 
inhibition of MDSC maturation, accumulation, function or 
differentiation, such as sunitinib, celecoxib, all-trans retinoic 
acid (ATRA), aminobisphosphonates, nitroaspirin and others 
(59,67). Importantly, the therapeutic effects of many of 
these compounds are only clear when used in combination 
with immunotherapy, emphasing that combination of 
immunotherapy with MDSC inhibition is, at present, a very 
promising anti-tumor strategy (67). 
Finally, the combination of adoptive T cell therapy with 
cancer vaccines has shown promising results in early clinical 
trials in cancer patients. However, this kind of therapy is 
associated with significant hurdles concerning cost and 
technical challenges (68). 
Evaluation Criteria
As a consequence of the complex biological interactions 
induced by immunotherapy without or with chemotherapy, 
there is a need to develop new response evaluation criteria 
for cancer vaccine therapy. The commonly used RECIST 
criteria (Response Evaluation Criteria in Solid Tumours) 
(69) are based on cytotoxic therapies that are directed to all 
dividing cells i.e. chemotherapy. This may lead to dramatic 
responses, even for bulky disease. Despite this, responses 
may be shortlasting. Immunotherapy is not expected to 
induce a speedy response with significant tumor reduction. 
The added value of immunotherapy lies in prolonged 
disease stabilization. This is however not measured in the 
commonly used RECIST criteria. Moreover, stabilization after 
initial progression during immunotherapy is probably also a 
favorable outcome. Overall survival and time to progression 
seem to be more appropriate to evaluate the effect of 
immunotherapy. These considerations were recently taken 
into account to evaluate a population treated with Ipilimumab. 
The authors declared 4 new response patterns, all associated 
with a favorable survival : (a) shrinkage in baseline lesions, 
without new lesions; (b) durable stable disease (in some 
patients followed by a slow, steady decline in total tumor 
burden); (c) response after an increase in total tumor burden; 
and (d) response in the presence of new lesions (70). 
Conclusion
Recurrent endometrial carcinoma and high grade uterine 
sarcoma are highly aggressive and reluctant to current 
treatment modalities and therefore new treatment options 
are needed. Worldwide, targeted therapies are gaining 
importance in the field of cancer treatment, among which 
immunotherapy. However, in uterine cancer it is a relatively 
new field. Attempts have been made, though the applied 
therapies were very diverse and not fundamentally (in vitro 
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and animal research) based, so that firm conclusions about 
effectiveness cannot be drawn. Nevertheless, increasing 
evidence becomes available pointing to a role of the immune 
system in uterine cancer, indicating that immunotherapy 
holds much promise. Moreover, proofs-of-concept from other 
malignancies also favors the combination of immunotherapy 
with existing therapies such as chemotherapy. Therefore, 
the immunotherapeutic field should deserve more attention 
in future fundamental and clinical research in uterine cancer. 
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